KRAS and neoplasm: Among patients with KRAS wild-type tumours, those with high AURKA-CN tumours had prolonged PFS compared with patients with low AURKA-CN tumours (HR=0.43, 95% CI: 0.19–0.94, P=0.04; Figure 3B).